Survey – Colibri Phototherapy

Dear Colleague, this is a short survey to assess your opinion about the use of the Colibri Phototherapy in your neonatal intensive care unit (NICU). The participation in the survey takes about 5 minutes of your time.

A. General Information

3. How many patients per year (approximately) do you treat with phototherapy at your NICU?

B. Device Performance

6. Coverage area (light reaching the infant’s skin) is sufficient(required)

C. Usability & Alarms

D. Safety

12. Have you observed any unexpected side effects during use?(required)

Yes No

Comment

13. Have you encountered any device malfunctions?(required)

Yes No

Comment

E. Misuse / Off-Label Use

14. Have you observed any misuse?(required)

Yes No

Comment

15. Have you observed off-label use (e.g., infants >10 kg)?(required)

Yes No

Comment

F. Clinical Benefit

NOTE: Following questions should base on your general clinical observations of therapy. Patient data or measured outcomes are not requested.

16. The expected clinical benefit of Colibri is an average 36% degradation of Total Serum Bilirubin (TSB) after an average 60-hour treatment. Does the device generally meet this expectation?(required)

Yes, consistently (TSB reduces by ~36% or more) Yes, sometimes (TSB reduces, but often less than 36%) No, reduction is significantly slower Not sure / Do not track specific percentage

17. On average, how many days of phototherapy do your patients usually require when using Colibri?(required)

Less than 2 days 2 – 3 days (matches expected average) More than 3 days

If available, please record representative cases below:

PATIENT 1

TSB

Baseline

Discharge

Duration of treatment (hours)

PATIENT 2

TSB

Baseline

Discharge

Duration of treatment (hours)

Thank you for your response. ✨